Status:
UNKNOWN
Translation and Validation of MESA Questionnaire of Chinese Language Version
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Conditions:
Questionnaire
Mixed Urinary Incontinence
Eligibility:
FEMALE
18-80 years
Brief Summary
The study is to translate the Medical, Epidemiologic, and Social aspects of Aging (MESA) urinary incontinence questionnaire into a Chinese language version and test the reliability and validity among ...
Detailed Description
Mixed urinary incontinence(MUI) is regarded as urgency-predominant when urgency incontinence episodes dominate over stress incontinence episodes, and vice versa. The treatment of MUI often begins with...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Female patients diagnosed with MUI in accordance with EAU guideline by history taking, physical examination, laboratory tests and specialist diagnosis;
- Age between 18 and 80 years old;
- At least 4 episodes of UUI in 3-day voiding diary;
- With MUI for at least 3 months, and urgency urinary incontinence dominates more than 50% of the total incontinence episodes in 3-day voiding diary;
- Positive cough test;
- A voluntarily-signed written informed content. For patients in group 1, inclusion criteria of 1), 2), 5) and 6) are required to meet. Those also meeting the criteria of 3) and 4) will enter group 2 at the same time.
- For patients in group 2 and groups 3, all inclusion criteria are required to meet.
- Exclusion criteria
- Having pure SUI, pure UUI, overflow UI or neurogenic bladder;
- Uncontrolled urinary tract infection;
- Tumor in urinary system or pelvic organs;
- Pelvic organ prolapse≥degreeⅡ;
- Residual urine volume≥100ml;
- Maximum flow rate\<15ml/s;
- In the past 1 month, receiving treatment of acupuncture or positive medications targeted at incontinence, such as antimuscarinic drugs;
- Underwent anti-incontinence or pelvic organ surgery, including metrectomy;
- Complication of severe diabetes or hypertension;
- Complication of diseases in nervous system that could hamper hypourethral function, such as multiple sclerosis, senile dementia, Parkinson's disease, spinal cord injury, cauda equina nerve injury and multiple system atrophy;
- Severe complications in cardiac, lungs, cerebrum, hepar, renal system, psychonosology and coagulation function, or obvious cognitive disability;
- Installed a cardiac pacemaker;
- Allergic to Solifenacin or with contraindications to antimuscarinic drug, including urinary retention, gastrointestinal peristalsis paralysis, myasthenia gravis, ulcerative colitis and angle-closure glaucoma;
- Allergic to metal or intolerant to the stimulation of electroacupuncture;
- Pregnant or plan to conceive in the future 1 year, or delivery in the past one year.
Exclusion
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03803878
Start Date
March 1 2019
End Date
December 30 2022
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guang An Men Hospital
Beijing, China, 100053